Rodman & Renshaw disclosed Cancer Genetics (NYSE:CGIX), boosting its price target to $6.00 earlier today
- Updated: September 26, 2016
Reporting as potential upside of 2.14%, Rodman & Renshaw upped the price target of Cancer Genetics (NYSE:CGIX) to $6.00
On Tuesday March 15, 2016, Aegis Capital released a statement about Cancer Genetics (NYSE:CGIX) dropped the target price from $15.00 to $8.00 that suggested an upside of 2.09%.
Having a price of $1.91, Cancer Genetics (NYSE:CGIX) traded -3.30% lower on the day. With the last stock price down -22.42% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CGIX has recorded a 50-day average of $2.08 and a two hundred day average of $2.27. Trade Volume was down over the average, with 45,135 shares of CGIX changing hands under the typical 97,747
Recent Performance Chart
Cancer Genetics has with a one year low of $1.72 and a one year high of $9.50 and has a market capitalization of $0.
A total of 3 brokerages have issued a ratings update on Cancer Genetics. Two brokerages rating the company a strong buy, one brokerage rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $8.42.
General Company Details For Cancer Genetics (NYSE:CGIX)
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.